| Mitochondrial function as a therapeutic target in heart failure | 2016/12/22 | English | 458 |
| Epidemiology of valvular heart disease in the adult | 2011/01/25 | English | 451 |
| Myofibroblast-mediated mechanisms of pathological remodelling of the heart | 2012/12/04 | English | 445 |
| Macrophage subsets in atherosclerosis | 2014/11/04 | English | 442 |
| Nitric oxide signalling in cardiovascular health and disease | 2018/02/01 | English | 439 |
| HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms | 2011/02/08 | English | 432 |
| Peripheral artery disease: epidemiology and global perspectives | 2016/11/17 | English | 420 |
| Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors | 2018/08/16 | English | 413 |
| The NLRP3 inflammasome in acute myocardial infarction | 2017/11/16 | English | 412 |
| Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities | 2019/03/07 | English | 408 |
| Dietary metabolism, the gut microbiome, and heart failure | 2018/11/08 | English | 407 |
| Regulatory mechanisms in vascular calcification | 2010/07/27 | English | 401 |
| The ABC pathway: an integrated approach to improve AF management | 2017/09/29 | English | 398 |
| Epidemiological studies of CHD and the evolution of preventive cardiology | 2014/03/25 | English | 382 |
| Thyroid hormones and cardiovascular disease | 2016/11/04 | English | 382 |
| Role of gut microbiota in atherosclerosis | 2016/12/01 | English | 380 |
| Mendelian randomization in cardiometabolic disease: challenges in evaluating causality | 2017/06/01 | English | 373 |
| Viral myocarditis—diagnosis, treatment options, and current controversies | 2015/07/21 | English | 372 |
| Ischaemic conditioning and reperfusion injury | 2016/02/04 | English | 368 |
| Epidemiology of cardiovascular disease in young individuals | 2017/10/12 | English | 368 |
| Abdominal aortic aneurysm: update on pathogenesis and medical treatments | 2018/11/15 | English | 368 |
| Environmental factors in cardiovascular disease | 2015/10/13 | English | 363 |
| SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | 2020/07/14 | English | 357 |
| Reappraising the role of inflammation in heart failure | 2020/01/22 | English | 354 |
| Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine | 2020/02/03 | English | 353 |
| Depression and coronary heart disease | 2016/11/17 | English | 352 |
| Redefining the identity of cardiac fibroblasts | 2017/04/24 | English | 352 |
| Small-diameter vascular tissue engineering | 2013/05/21 | English | 351 |
| Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence | 2020/02/20 | English | 348 |
| Metabolic remodelling in heart failure | 2018/06/18 | English | 347 |